Fc Protein and Glycoengineered Antibodies Market

Fc Protein and Glycoengineered Antibodies
Market – Size, Share, Outlook, and Opportunity
Analysis, 2019 – 2027
Monoclonal antibodies are developed by identical immune cells, which have a therapeutic use.
The crystallized fragments (Fc) protein and glycoengineered antibodies are known as the next
generation antibodies. These monoclonal antibodies are immunoglobulin G (IgG) type of
molecules, which are attached to a glycan residue on crystallisable fragment. Glycoengineering
is the method by which these antibodies are created. They have varied applications for the
treatment of diseases such as multiple sclerosis and cancers.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/2626
Global Fc Protein and Glycoengineered Antibodies Market Drivers
Key players in the market are focusing on research and development activities and receiving
approvals from regulatory bodies, which are expected to boost the global Fc protein and
glycoengineered antibodies market growth over the forecast period.
For instance, in 2016, Genentech Inc. received approval from the U.S. Food and drug
Administration (U.S. FDA) for Tecentriq (Atezolizumab). It is being used for the treatment of
urothelial carcinoma. In March 2019, Tecentriq received its second approval from the U.S. FDA
for the treatment of small lung cancer. Furthermore, in November 2017, TG Therapeutics, Inc.
began its clinical trial of Ublituximab for the treatment of multiple sclerosis. It is currently in
third phase of its clinical trial. Factors such as increasing product approvals and robust pipeline
are expected to drive the global fc protein and glycoengineered antibodies market growth.
Increasing prevalence of diseases such as cancer is expected to propel the global Fc protein and
glycoengineered antibodies market growth. According to the World Health Organization (WHO),
cancer is considered as the second most leading cause of death worldwide, and, in 2018,
around 9.6 million people died worldwide due to cancer. Hence, glycoengineered antibodies can
be developed for the treatment of cancer and thus, this factor is expected to drive growth of
the global fc protein and glycoengineered antibodies market over the forecast period.
Report includes chapters which deeply display the following deliverable about industry :
• Fc Protein and Glycoengineered Antibodies Market Research Objective and Assumption
• Fc Protein and Glycoengineered Antibodies Market Purview - Report Description, Executive
Summary, and Coherent Opportunity Map (COM)
• Fc Protein and Glycoengineered Antibodies Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Fc Protein and Glycoengineered Antibodies Market, By Regions
• Fc Protein and Glycoengineered Antibodies Market Competition by Manufacturers including
Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and
Product Type.
• Fc Protein and Glycoengineered Antibodies Market Manufacturers Profiles/Analysis including
Company Basic Information, Manufacturing Base and Its Competitors.
• Fc Protein and Glycoengineered Antibodies Market Manufacturing Cost Analysis including Key
Raw Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Fc Protein and Glycoengineered Antibodies Market Forecast including Production,
Consumption, Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Global Fc Protein and Glycoengineered Antibodies Market Restraints
High cost of drugs is expected to hinder the global Fc protein and glycoengineered antibodies
market growth. Manufacturers are focused on offering a highly effective drug, thus investing
more into research and development activities. This increases the final cost price of the product.
According to Pharmacy and Healthcare Communication, LLC, Gazyva costs around US$ 41,300
for six months treatment of cancer. Hence, this factor is expected to restrain growth of the
global fc protein and glycoengineered antibodies market.
Global Fc Protein and Glycoengineered Antibodies Market Regional Analysis
North America region is expected to dominate in the global fc protein and glycoengineered
antibodies market due to factors such as product launches, presence of leading manufacturers
(such as F. Hoffmann La-Roche Ltd.), and active research and development in the field. Drugs
such as Obinutuzumab (Gazyva), Mogamulizumab (Poteligeo), Atezolizumab (Tecentriq), and
Durvalumab (Imfinzi) have been approved in the U.S. in 2013, 2018, 2016, and 2017
respectively.
Europe is expected to witness significant growth in the global Fc protein and glycoengineered
antibodies market. Factors such as approval for new drugs is expected to drive the Europe’s Fc
protein and glycoengineered antibodies market growth over the forecast period. For instance, in
2018, Kyowa Hakko Kirin Co. Ltd. received an approval from the European Commission to
market the Poteligeo antibody in the European market. It is the first biological product that is
being directed against chemokine receptor 4 (CCR4), which will be used for the treatment of
Sezary syndrome that has been previously treated by systemic therapy. Such new drug
approvals are expected to propel Europe Fc protein and glycoengineered antibodies market
growth over the forecast period.
Global Fc Protein and Glycoengineered Antibodies Market Key Players
Some of the major players operating in the global Fc protein and glycoengineered antibodies
market include Kyowa Hakko Kirin Co. Ltd., Merck KGaA, Boehringer Ingelheim International
GmbH, AstraZeneca Plc, Amgen Inc., Genentech Inc., Five Prime Therapeutics Inc., Celldex
Therapeutics, Clovis Oncology, and TG Therapeutics, Inc.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/2626
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Monoclonal antibodies are developed by identical immune cells, which have a therapeutic use.

Download Report